Analyze the current US equity market regime using public market data, sector rotation, relative strength, breadth, leadership concentration, market participation, defensive vs cyclical behavior, volatility, small vs large caps, and growth vs value. Generate a modern visual dashboard with transparent data confidence and proxy labeling — research only, with no buy/sell calls, allocation advice or trading instructions.
A read-only tool that describes the risk in your stock/ETF holdings: a 0-100 portfolio risk score, a risk level for each holding, factor exposure, four hypothetical stress scenarios, and how your exposure compares with reference limits for your chosen style. It does not recommend trades or quantities and is not investment advice.
Three independent AI reviewers audit your investor update for vague claims, buried bad news, and fuzzy asks, then cross-examine each other before a board verdict.
Paste current and prior annual-report risk excerpts for a source-bounded change brief that separates new wording, removed wording, supported implications, and review questions.
Turn pasted operating metrics, risks, and decision requests into a concise board-update storyboard. Keep values traceable, expose gaps, and separate supplied facts from proposals.
一行指令拿到任何標的的日線技術面全景，AI 直接讀成人話：現在是趨勢還是盤整、現價站在哪些均線之上、哪些訊號正在互相打架。最後一項是散戶最常漏掉的——綜合評分寫「買進」但 RSI 超買加 ADX 低於 20，那不是趨勢，是假突破。支援美股、期貨、加密貨幣、外匯、台股。免 API key、零依賴，純讀取不碰你的帳戶。
Track what insiders and 13 top funds, from Berkshire to Pershing Square, are buying and selling, straight from SEC filings. Fund-by-fund 13F changes, consensus buys, any-ticker lookup and insider red flags, every number linked to its source.
Built on clinical epidemiology, biostatistics, causal inference, and evidence-based medicine. TrialReviewer analyzes RCTs, observational studies, meta-analyses, and diagnostic research using effect sizes, survival analysis, bias detection, GRADE, and benefit-harm frameworks to judge whether findings are valid, meaningful, and practice-changing.